Difference between revisions of "CNS carcinoma"
Jump to navigation
Jump to search
m (→NCCN) |
Warner-admin (talk | contribs) m (Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.") |
||
Line 15: | Line 15: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Guidelines= | =Guidelines= | ||
− | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any | + | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' |
==[http://www.asco.org/ ASCO]== | ==[http://www.asco.org/ ASCO]== | ||
*'''2022:''' Schiff et al. [https://doi.org/10.1200/jco.22.00333 Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline] [https://www.ncbi.nlm.nih.gov/pubmed/35561283 PubMed] | *'''2022:''' Schiff et al. [https://doi.org/10.1200/jco.22.00333 Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline] [https://www.ncbi.nlm.nih.gov/pubmed/35561283 PubMed] |
Revision as of 19:35, 20 December 2023
Section editor | |
---|---|
Seema Nagpal, MD Stanford University Palo Alto, CA, USA |
This page has regimens and guidelines that are not specific to any one type of cancer. For disease-specific regimens and guidelines, please go to the following pages:
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ASCO
- 2022: Schiff et al. Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline PubMed
ASCO/SNO/ASTRO
- 2021: Vogelbaum et al. Treatment for Brain Metastases PubMed
EANO/ESMO
- 2021: Le Rhun et al. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours PubMed
- 2017: Le Rhun et al. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours PubMed
NCCN
- NCCN does not have guidelines at this granular level; please see NCCN Guidelines - Central Nervous System Cancers.
All lines of therapy
Whole brain irradiation
WBRT: Whole-Brain Radiation Therapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Knisely et al. 2007 (RTOG 0118) | 2002-2004 | Phase 3 (C) | Thalidomide & WBRT | Did not meet primary endpoint of OS |
References
- RTOG 0118: Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ Jr, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):79-86. Epub 2007 Dec 31. link to original article contains dosing details in abstract PubMed NCT00033254